NTPC Q4 results FY26 Preview, Expectations: Stable power demand to drive revenues up 6%; PAT seen falling 18%; dividend in focus - Markets

NTPC Q4 results FY26 Preview, Expectations: Stable power demand to drive revenues up 6%; PAT seen falling 18%; dividend in focus – Markets

State-run power major NTPC Ltd is set to announce its earnings for the fourth quarter of the financial year 2025-26. Along with the quarterly results, the PSU might also declare a dividend for its shareholders. State-owned power generation giant NTPC Ltd is expected to report a steady top-line performance in the January-March quarter of FY26,…

Read More
Buyback boom gains pace as firms deploy excess cash; tech, pharma may lead: Equirus Capital

Buyback boom gains pace as firms deploy excess cash; tech, pharma may lead: Equirus Capital

Bhavesh Shah, Managing Director and Head, Investment Banking at Equirus Capital believes companies are increasingly viewing buybacks as an efficient way to return surplus cash to shareholders during a volatile market environment. He added that SEBI’s rule changes have made buybacks “more palpable from a taxation perspective and more market-friendly.” The trend comes after regulatory…

Read More
Alembic Pharma gets USFDA nod for thyroid disorder and cancer treatment drug

Alembic Pharma gets USFDA nod for thyroid disorder and cancer treatment drug

Alembic Pharmaceuticals Ltd. on Friday, May 22, said it has received the final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Levothyroxine Sodium Tablets USP across multiple dosage strengths. The approved product is therapeutically equivalent to AbbVie Inc.’s Synthroid Tablets and is available in strengths ranging…

Read More